Press Release | October 13, 2026
āshibio Presents Preliminary Efficacy Data for Andecaliximab Demonstrating an 86.2% Reduction in New Flare-Up Rate in Patients with FOP
Read More
Press Release | October 13, 2026
āshibio Presents Biomarker Data Supporting Vantictumab Development for ADO2 and a Prevalence Estimate of CLCN7-Related ADO2 of 1–4 per 20,000 Individuals
Read More
Press Release | October 9, 2026
TRexBio Announces Pricing of Initial Public Offering
Read More
Press Release | October 5, 2026
Introducing Fierce Biotech’s 2026 Fierce 15
Read More
